Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.06), $0.05 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $14 million versus the consensus estimate of $13.05 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.